CD274 and cancer: The survival of patients with many types of cancer, especially melanoma and lung, renal, head, neck, and liver cancers, has improved in recent years with the advances in the domain of cancer immunotherapies, especially ICIs, such as anti-PD-1 and anti-PD-L1.